Epsilon Healthcare Limited

ASX:EPN Stok Raporu

Piyasa değeri: AU$7.2m

Epsilon Healthcare Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 16.1% per year.

Anahtar bilgiler

-4.2%

Kazanç büyüme oranı

9.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi31.2%
Gelir büyüme oranı16.1%
Özkaynak getirisi-64.7%
Net Marj-82.2%
Son Kazanç Güncellemesi30 Jun 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?

Oct 13
Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Jun 30
Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt

Sep 26
We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt

Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?

Jun 13
Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Feb 27
Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Gelir ve Gider Dağılımı

Epsilon Healthcare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:EPN Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 237-650
31 Mar 237-1060
31 Dec 227-1360
30 Sep 226-1370
30 Jun 225-1370
31 Mar 225-1180
31 Dec 215-9100
30 Sep 216-9110
30 Jun 217-9120
31 Mar 217-10110
31 Dec 207-11110
30 Sep 207-11110
30 Jun 206-12110
31 Mar 205-12100
31 Dec 195-12100
30 Sep 194-1190
30 Jun 194-1190
31 Mar 193-1090
31 Dec 183-980
30 Sep 183-770
30 Jun 183-560
31 Mar 182-450
31 Dec 172-330

Kaliteli Kazançlar: EPN is currently unprofitable.

Büyüyen Kar Marjı: EPN is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Büyüme Hızlandırma: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).


Özkaynak Getirisi

Yüksek ROE: EPN has a negative Return on Equity (-64.69%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin